Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. Covid-19 Vaccine Donation to Boost Developing World's Pandemic Fight -- Update

06/10/2021 | 05:23pm EDT

By Gabriele Steinhauser and Saeed Shah

A plan to revive a stumbling campaign to get Covid-19 vaccines to developing countries got a critical boost from U.S. plans to donate 500 million shots developed by BioNTech SE and Pfizer Inc. by next June, part of an expected announcement by a group of world leaders that they will provide one billion doses.

While rich countries in North America and Europe have largely immunized their high-risk citizens and are now moving to vaccinate teenagers ahead of the new school year, many poor nations are facing new surges in infections with little protection. In Africa, for instance, just 0.6% of the population has been fully vaccinated, compared with 42% in the U.S.

The developing world has emerged as the focal point of the pandemic, with infections and deaths reaching new records in recent months in part because of low vaccination rates.

After the U.S. said it would donate the 500 million doses, British Prime Minister Boris Johnson's office said Thursday that the U.K. will donate 100 million surplus vaccine doses to the rest of the world within the next year. Those commitments are part of at least one billion doses world leaders are expected to say they will provide "through dose sharing and financing and set out a plan to expand vaccine manufacturing in order to achieve that goal," Mr. Johnson's office said ahead of the Group of Seven summit.

Health officials in developing countries said ahead of the summit that they hope the 500 million doses due to be donated by the U.S. will encourage other rich governments to step up. The announcement "is a monumental step forward" in the global effort to get vaccines to poor countries, said Matshidiso Moeti, the World Health Organization's director for the Africa region. "We are now seeing wealthy nations starting to turn promises into action."

President Biden said the U.S. isn't perfect but steps up in times of need. He also acknowledged it was in America's public health and economic interests to donate the vaccines.

"As long as the virus rages elsewhere, there is a risk of new mutations that could threaten our people," he said. "We know that raging COVID-19 in other countries holds back global growth, raises instability and weakens governments."

Deliveries of the U.S.'s donated shots will start in August and reach 200 million doses by the end of the year, the two companies said Thursday. The remaining 300 million doses are due to be shipped by June 2022.

How to close the global vaccination gap, caused largely by rich governments buying up much of the supply for 2021, is set to be at the center of talks among leaders of the Group of Seven leading economies starting Friday. Mr. Johnson, who is hosting the summit, has called on the G-7 leaders to commit to vaccinating the entire world by the end of 2022.

The August deliveries of the Pfizer-BioNTech shots will help plug an immediate gap of 250 million vaccines faced this summer by the WHO-backed Covax initiative, which aims to get Covid-19 shots to 30% of adults in the world's poorest countries by early 2022. The U.S. has previously said that it would share 80 million vaccines with other countries, including through Covax, by the end of this month.

A spokeswoman for Gavi, the Vaccine Alliance, which helps run Covax, said it "welcomes this important contribution to Covax, which will see more vaccines put to work protecting some of the most vulnerable people in the world."

Covax has struggled to keep up shipments since March, when the Indian government imposed an export ban on its main supplier, the Serum Institute of India, which is making a vaccine developed by AstraZeneca Inc. and the University of Oxford. India has diverted the vaccines to inoculate its own population in an effort to slow a devastating outbreak at home. Many of the 92 countries most dependent on Covax have yet to finish immunizing healthcare workers, tens of millions of whom are waiting to receive a second AstraZeneca dose in the coming weeks.

The donation of the Pfizer doses reflects a broader shift in U.S. vaccination policy. Washington has so far kept a tight lid on the export of shots, a stance that has been criticized by its European allies and developing countries. Pfizer said Thursday that it expects the 500 million doses to come from its manufacturing facilities in the U.S. and that it is selling the vaccine at what it called a not-for-profit price.

Biden administration officials said the 500 million shots will cost about $3.5 billion, with the contract due to be finalized in the coming weeks. That suggests a price of $7 a dose, far below the $19.50 the U.S. paid in its previous supply deal. About $2 billion of the overall cost will be covered by the administration's previous $4 billion commitment to Covax. An additional $1.5 billion will come from money included in the coronavirus-relief law Mr. Biden signed earlier this year.

The International Monetary Fund and other multilateral agencies estimated this month that it will cost $50 billion to vaccinate at least 60% of the population in developing countries in an effort to end the pandemic by mid-2022. That includes investments needed to build out the infrastructure to effectively roll out Covid-19 shots in poor countries as well as new manufacturing capacity and should help cover some of the costs of Covid-19 tests and treatments and other public-health measures.

G-7 leaders are expected to make new announcements on how to raise those funds at their summit.

A shift from the relatively easy-to-store AstraZeneca shot in the global inoculation effort to the Pfizer-BioNTech shot adds new urgency to raising more funds. The Pfizer-BioNTech vaccine needs to be stored in sophisticated freezers that can keep it at minus 70 degrees Celsius, which aren't commonly available in many developing countries.

John Nkengasong, the director of the Africa Centres for Disease Control and Prevention, said Thursday he was confident that the Pfizer shot could be rolled out in major African cities, where electricity supply is more reliable. "My position has always been: If you give me Pfizer shots I will use them on the continent," he said.

Write to Gabriele Steinhauser at gabriele.steinhauser@wsj.com and Saeed Shah at saeed.shah@wsj.com

(END) Dow Jones Newswires

06-10-21 1923ET

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.34% 8322 Delayed Quote.14.01%
BIONTECH SE -2.96% 229.5 Delayed Quote.190.10%
DJ INDUSTRIAL -0.21% 33874.24 Delayed Quote.10.91%
DOW JONES AFRICA TITANS 50 INDEX -0.18% 527.96 Delayed Quote.-0.39%
PFIZER, INC. -1.41% 39.05 Delayed Quote.7.61%
S&P AFRICA 40 INDEX 0.48% 170.16 Delayed Quote.-1.99%
All news about BIONTECH SE
03:12pMODERNAá : NIH begins clinical trial testing COVID-19 vaccine in pregnant women
11:56aEuropean ADRs Edge Higher in Wednesday Trading
11:49aUS' CDC To Study Possible Link Between Heart Inflammation And Pfizer/BioNTech..
10:17aBIONTECHá : EMA - Two additional manufacturing sites for BioNTech Pfizer's COVID..
10:16aGLOBAL MARKETS LIVE : Microsoft, Morgan Stanley, Heineken, Twitter, AstraZeneca...
10:03aSIEMENSá : To Provide Technology Support For BioNTech's Vaccine Production Sites
09:08aToday on Wall Street: We shall not be ruled by inflation fears
08:20aSiemens, BioNTech to Expand Vaccine Production Collaboration
02:11aDebate Intensifies Over A Vaccine IP Waiver's Impact On Future Pharma And Bio..
01:02aSECTORAL ASSET MANAGEMENTá : Covid-Vaccine Patent Waiver: Will it Increase World..
More news
Sales 2021 12 387 M 14 783 M 14 783 M
Net income 2021 7 065 M 8 431 M 8 431 M
Net cash 2021 7 669 M 9 152 M 9 152 M
P/E ratio 2021 7,00x
Yield 2021 -
Capitalization 47 849 M 57 117 M 57 102 M
EV / Sales 2021 3,24x
EV / Sales 2022 3,23x
Nbr of Employees 2 200
Free-Float 87,3%
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 13
Last Close Price 198,12 €
Average target price 148,37 €
Spread / Average Target -25,1%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Sierk P÷tting Chief Operating & Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE190.10%57 117
WUXI APPTEC CO., LTD.36.51%68 536
BEIGENE, LTD.28.69%30 775